

AstraZeneca Development Pipeline
31 January 2008

Line Extensions

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing	
				MAA	NDA
Cardiovascular					
<i>Atacand</i>	angiotensin II antagonist	diabetic retinopathy	III	1H 2009	1H 2009
<i>Atacand Plus</i>	angiotensin II antagonist/thiazide diuretic	32/12.5 mg, 32/25 mg for hypertension	III	2Q 2008	
<i>Crestor</i>	statin	atherosclerosis	III	Launched	Launched
<i>Crestor</i>	statin	outcomes End Stage Renal Disease	III	1H 2009	1H 2009
<i>Crestor</i>	statin	outcomes in subjects with elevated CRP	III	2010	2010
<i>Saxagliptin/Metformin FDC</i>	DPP-4 + biguanide FDC	diabetes	III		
<i>Dapagliflozin/Metformin FDC</i>	SGLT2 + biguanide FDC	diabetes	III		
Gastrointestinal					
<i>Nexium</i>	proton pump inhibitor	peptic ulcer bleeding	III	2Q 2008	2Q 2008
<i>Nexium Sachet formulation</i>	proton pump inhibitor	GERD	III	Approved**	Launched
<i>Nexium</i>	proton pump inhibitor	extra-oesophageal reflux disease	II	2H 2009*	2H 2009*
<i>Nexium low dose aspirin combination</i>	proton pump inhibitor	low dose aspirin associated peptic ulcer	III		1H 2009
Neuroscience					
<i>Seroquel XR</i>	D ₂ /5HT ₂ antagonist	schizophrenia	III	Approved	Launched
<i>Seroquel</i>	D ₂ /5HT ₂ antagonist	bipolar maintenance	III	2Q 2008	Filed
<i>Seroquel</i>	D ₂ /5HT ₂ antagonist	bipolar depression	III	1Q 2008	Launched
<i>Seroquel XR</i>	D ₂ /5HT ₂ antagonist	generalised anxiety disorder	III	4Q 2008	2Q 2008
<i>Seroquel XR</i>	D ₂ /5HT ₂ antagonist	major depressive disorder	III	3Q 2008	1Q 2008
<i>Seroquel XR</i>	D ₂ /5HT ₂ antagonist	bipolar mania	III	1Q 2008	Filed
<i>Seroquel XR</i>	D ₂ /5HT ₂ antagonist	bipolar depression	III	1Q 2008	Filed
Oncology & Infection					
<i>Faslodex</i>	oestrogen receptor antagonist	1 st line advanced breast cancer	III		
<i>Faslodex</i>	oestrogen receptor antagonist	adjuvant	III		
<i>Iressa</i>	EGFR-TK inhibitor	NSCLC	III	2Q 2008	
<i>FluMist (MedImmune)</i>	live, attenuated, intranasal influenza virus vaccine	influenza	III	2Q 2008	Launched

*Project Extraesophageal reflux disease (reflux asthma) will be completed but will not result in a regulatory filing.

** Approved by EU RMS, Mutual Recognition Procedure ongoing

Line Extensions (continued)

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing	
				MAA	NDA
Respiratory & Inflammation					
<i>Symbicort</i> pMDI	inhaled steroid/fast onset, long-acting β_2 agonist	asthma	III	Filed*	Launched**
<i>Symbicort</i> pMDI	inhaled steroid/fast onset, long-acting β_2 agonist	COPD	III	Filed*	2Q 2008

*To be supplemented in 2008 with data supporting two additional strengths.

**US approval based on 12 years and above.

NCE's

Phase III

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing	
				MAA	NDA
Cardiovascular					
AZD6140	ADP receptor antagonist	arterial thrombosis	III	2H 2009	2H 2009
Saxagliptin	dipeptidyl peptidase-4 (DPP-4) inhibitor	diabetes	III	2H 2009	2Q 2008
Dapagliflozin	sodium-glucose cotransporter-2 (SGLT2) inhibitor	diabetes	III	2010	2010
<i>Crestor/ABT-335</i>	statin + fibrate fixed combination	dyslipidaemia	III		2H 2009
Neuroscience					
PN400	naproxen +esomeprazole	signs and symptoms of OA , RA, and AS	III	1H 2009	1H 2009
Oncology & Infection					
<i>Zactima</i>	VEGF/EGF TK inhibitor with RET kinase activity	NSCLC	III	4Q 2008	4Q 2008
<i>Recentin</i>	VEGF signalling inhibitor (VEGFR-TKI)	NSCLC and CRC	II/III	2010	2010
<i>Recentin</i>	VEGF signalling inhibitor (VEGFR-TKI)	recurrent glioblastoma	III	2010	2010
ZD4054	endothelin A receptor antagonist	hormone resistant prostate cancer	III	2011	2011
Motavizumab (MedImmune)	humanized monoclonal antibody	RSV prevention	III	1H 2009	1Q 2008

NCE's

Phases I and II

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing	
				MAA	NDA
Cardiovascular					
AZD0837	thrombin inhibitor	thrombosis	II	2012	2012
AZD4121	cholesterol absorption inhibitor	dyslipidaemia	II		
AZD2207	CB1 antagonist	diabetes/obesity	II		
AZD1175	CB1 antagonist	diabetes/obesity	I		
AZD1305	antiarrhythmic	arrhythmias	I		
AZD6370	GLK activator	diabetes	I		
Gastrointestinal					
AZD3355	inhibitor of transient lower oesophageal sphincter relaxations (TLESR)	GERD	II	2011	2011
AZD2066	metabotropic Glutamate receptors subtype 5	GERD	I		
AZD1386	Vanilloid receptor 1 antagonist	GERD	I		
Neuroscience					
AZD3480	neuronal nicotinic receptor agonist	cognitive disorders in schizophrenia	II	2011	2011
AZD3480	neuronal nicotinic receptor agonist	Alzheimers	II	2011	2011
AZD6765	NMDA receptor antagonist	depression	II		
AZD2327	enkephalinergic receptor modulator	anxiety and depression	I		
AZD5904	inhibitor of myeloperoxidase (MPO)	multiple sclerosis	I		
AZD3241	inhibitor of myeloperoxidase (MPO)	Parkinson's disease	I		
AZD0328	selective neuronal nicotinic receptor agonist	Alzheimers	I		
AZD1940	CB receptor agonist	nociceptive and neuropathic pain	I		
AZD2624	NK receptor antagonist	schizophrenia	I		
AZD1386	Vanilloid receptor antagonist	chronic nociceptive pain	I		
AZD2066	metabotropic Glutamate receptors	chronic nociceptive pain	I		
AZD7325	GABA receptor subtype partial agonist	anxiety	I		
AZD6280	GABA receptor subtype partial agonist	anxiety	I		
TC-5619 (Targacept)	neuronal nicotinic receptor agonist	cognitive disorders in schizophrenia	I		

Phases I and II (continued)

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing	
				MAA	NDA
Oncology & Infection					
<i>Zactima</i>	VEGF/EGF TK inhibitor with RET kinase activity	medullary thyroid cancer	II	4Q 2008	4Q 2008
<i>CytoFab</i>	anti-TNF-alpha polyclonal antibody	severe sepsis	II		
AZD6244 (ARRY-142886)	MEK inhibitor	solid tumours	II		
AZD2281	PARP inhibitor	breast cancer	II		
EBV vaccine*	Epstein-Barr Virus Vaccine	post-transplant proliferative disease	II		
AZD2836	5a replicon	hepatitis C	II		
AZD0530	SRC kinase inhibitor	solid tumours and haematological malignancies	II		
MEDI-524 (Motavizumab)	MAb targets F-Protein	early and late treatment of disease in paed >1 yr	II		
MEDI-561	HSP 90 inhibitor	solid tumours	II		2010
AZD1152	aurora kinase inhibitor	solid tumours and haematological malignancies	I		
AZD4769	EGFR tyrosine kinase inhibitor	solid tumours	I		
AZD4877	Cell Cycle Agent	solid tumours and haematological malignancies	I		
AZD8931	erbB kinase inhibitor	solid tumours	I		
AZD7762	CHK1 Kinase Inhibitor	solid tumours	I		
AZD8330 (ARRY-424704)	MEK inhibitor	solid tumours	I		
CAT-8015	recombinant immunotoxin	haematological malignancies	I		
MEDI-534	RSV/PIV-3 vaccine	intranasal immunisation	I		
MEDI-560	PIV-3 vaccine	intranasal immunisation	I		
H5N1	H5N1 Influenza Virus Vaccine	pandemic influenza vaccine	I		
MEDI-538	CD19 B cells	leukaemia/lymphoma	I		
MEDI-564	F protein inhibitor	RSV treatment	I		
CMV Vaccine	CMV vaccine	cytomegalovirus	I		
MEDI-557	YTE – extended half-life RSV Mab	RSV Prophylaxis	I		

*Partnered product

Phases I and II (continued)

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing	
				MAA	NDA
Respiratory & Inflammation					
AZD9056	ion channel blocker (P2X7)	rheumatoid arthritis	II	2012	2012
AZD1981	Prostaglandin receptor antagonist	asthma	II		
AZD5672	Chemokine antagonist (CCR5)	rheumatoid arthritis	II	2012	2012
MEDI-528	anti-IL-9 antibody	asthma	II		
AZD4818	CCR1 antagonist	COPD	I		
CAT-354	anti-IL-13 antibody	asthma	I		
AZD5904	MPO inhibitor	COPD	I		
AZD1744	Dual CCR3/H1 receptor antagonist	COPD	I		
AZD1236	Matrix metalloproteinase inhibition	COPD	I		
AZD9668	Neutrophil Elastase Inhibitor	COPD	I		
MEDI-563	anti-IL-5R antibody	asthma	I		
MEDI-545	anti-IFN α antibody	SLE, myositis	I		
Pneumococcal vaccine*	Pneumococcal vaccine	Streptococcus pneumoniae	I		
AZD3199	iLABA	asthma/COPD	I		
CAM-3001	anti-GM-CSFR antibody	rheumatoid arthritis	I		

*Partnered product

**AstraZeneca Development Pipeline
Discontinued Projects vs 26 July 2007 HY**

Cardiovascular & Gastrointestinal

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD1283	thrombosis
NCE	AZD3988	diabetes/obesity
NCE	AZD3118	arrhythmias
LE	Crestor Outcomes CHF	CHF
LE	Nexium NSAID GI US	ulcer healing
LE	Nexium NSAID GI side effects US	symptom resolution
NCE	AZD9056	Inflammatory bowel disease

Neuroscience

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD3783	anxiety & depression
NCE	AZD1080	Alzheimers

Oncology & Infection

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD6495	range of tumours
NCE	CAT-5001	solid tumours
NCE	AZD5180	solid tumours
NCE	hMPV MAb	respiratory infection
NCE	MEDI-552	leukaemia/lymphoma
NCE	MEDI-555	solid tumours
NCE	MEDI-562	solid tumours
NCE	CAT-3888	hairy cell leukaemia
NCE	AZD9935	solid tumours
NCE	AZD4992	breast cancer

Respiratory & Inflammation

NCE/Line Extension	Compound	Area Under Investigation
NCE	MEDI-552	inflammation
NCE	Anti-IL6 MAb	inflammation
NCE	anti Chitinase MAb	asthma/COPD
NCE	AZD6357	osteoarthritis
NCE	AZD6605	osteoarthritis

Comments

As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

Compounds in development are displayed by phase.

Projects shaded in grey were communicated as discontinued at the Biologics Review, Dec 7th 2007

Abbreviations:

MAA – Marketing Authorisation Application (Europe).

NDA – New Drug Application/Biologics Licensing Application (USA).